title: Intermittent treatment with sunitinib may achieve complete response in metastatic renal cell carcinoma.
authors.forename: G
authors.initials: G
authors.lastname: Aksu
authors.forename: F
authors.initials: F
authors.lastname: Ensaroglu
authors.forename: I
authors.initials: I
authors.lastname: Dolasik
authors.forename: S
authors.initials: S
authors.lastname: Temiz
authors.forename: H
authors.initials: H
authors.lastname: Halis
authors.forename: S Y
authors.initials: SY
authors.lastname: Sener
authors.forename: A
authors.initials: A
authors.lastname: Kaya
authors.forename: K
authors.initials: K
authors.lastname: Uygun
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D011758:Pyrroles / Q000627:therapeutic use*; D012074:Remission Induction; D000077210:Sunitinib; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib